Ironwood Pharmaceuticals (NASDAQ:IRWD) Announces Earnings Results

Ironwood Pharmaceuticals (NASDAQ:IRWD) posted its quarterly earnings results on Monday. The biotechnology company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15, Zacks reports. The business had revenue of $122.06 million for the quarter, compared to analysts’ expectations of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals updated its FY 2025 guidance to EPS.

Ironwood Pharmaceuticals Stock Up 6.9%

Ironwood Pharmaceuticals stock traded up $0.20 during mid-day trading on Wednesday, reaching $3.09. 1,329,838 shares of the company’s stock traded hands, compared to its average volume of 2,556,115. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.13. The stock has a 50 day moving average of $1.54 and a two-hundred day moving average of $1.07. The company has a market cap of $501.76 million, a price-to-earnings ratio of -60.69 and a beta of 0.37.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRWD. Dynamic Technology Lab Private Ltd bought a new stake in Ironwood Pharmaceuticals during the first quarter worth approximately $57,000. Captrust Financial Advisors bought a new position in shares of Ironwood Pharmaceuticals during the 2nd quarter valued at approximately $32,000. Engineers Gate Manager LP raised its holdings in Ironwood Pharmaceuticals by 369.2% during the 2nd quarter. Engineers Gate Manager LP now owns 73,354 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 57,720 shares during the period. Bridgeway Capital Management LLC lifted its position in Ironwood Pharmaceuticals by 141.9% in the second quarter. Bridgeway Capital Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $54,000 after buying an additional 44,000 shares during the last quarter. Finally, Strs Ohio purchased a new position in Ironwood Pharmaceuticals during the first quarter worth $113,000.

Analyst Ratings Changes

Several analysts recently issued reports on IRWD shares. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Wells Fargo & Company lifted their price objective on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the company an “equal weight” rating in a research report on Tuesday. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ironwood Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ironwood Pharmaceuticals currently has an average rating of “Hold” and an average price target of $5.34.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.